Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here


Lilly, Rigel enter $960m deal to develop RIPK1 inhibitors

Eli Lilly and Company and Rigel Pharmaceuticals have entered into a global exclusive license agreement and strategic collaboration to co-develop and commercialise the latter’s receptor-interacting serine / threonine-protein kinase 1…